A nomogram integrating mutation signatures and clinical features for prognostic stratification in bladder cancer
Authors:
Open Access
- 15 August 2025
- journal article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1562
Abstract
Bladder cancer (BLCA) is a typical malignancy in the urinary tract, with a dismal survival rate and limited therapeutic options. There is a growing demand for clinically relevant biomarkers to effectively stratify prognosis. This study aims to develop a prognostic model utilizing mutation signatures and clinical characteristics to inform the clinical management of BLCA. The data of 631 BLCA patients were retrospectively reviewed, including 538 patients from The Cancer Genome Atlas (TCGA) and 93 patients from a Chinese cohort. Univariate and multivariate analyses were performed to identify the independent prognostic factors for overall survival (OS). Multivariate Cox regression analysis revealed that a 30-mutated gene signature and age were independent prognostic factors for BLCA. The prognostic nomogram was constructed to predict the probability of 1-, 3-, and 5-year OS, achieving area under the curve (AUC) values of 0.800, 0.749, and 0.731 in the training group, and 0.641, 0.820, and 0.759 in the validation group, respectively. Additionally, high risk scores were associated with poorer outcomes across all clinical subgroups. Patients with high-risk profiles exhibited higher neoantigen burden (p = 0.029), copy number variation (CNV) count (p = 0.013), and DNA damage response (DDR) mutations (p < 0.001) compared to those with low-risk profiles. The model incorporating mutation signatures and clinical factors demonstrated accuracy in predicting changing cancer survival risk over time.This suggests that the model has the potential to serve as a valuable prognostic tool for BLCA.Keywords
This publication has 51 references indexed in Scilit:
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial CancersJournal of Clinical Oncology, 2018
- Exome sequencing reveals the genetic landscape and frequent inactivation of PCDHB3 in Chinese rectal cancersThe Journal of Pathology, 2018
- Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging ContextsClinical Genitourinary Cancer, 2017
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisThe Lancet Oncology, 2017
- The focal adhesion-associated proteins DOCK5 and GIT2 comprise a rheostat in control of epithelial invasionOncogene, 2016
- ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cellsMolecular Cancer, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Negative regulation of the p300-p53 interplay by DDX24Oncogene, 2015
- Immunohistochemical biomarkers for bladder cancer prognosisInternational Journal of Urology, 2011
- Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instabilityOncogene, 2004